SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Income Before Tax
Profit after all operating and non-operating items but before income tax.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Income Before Tax · Q1 FY2026 · quarter ended Mar 2026
Income before tax of -$13.82M in Q1 FY2026
Q1 FY2026 income before tax was -$13.82M.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Before Tax history
USD · from the income statement
- Latest · FY2025
- (39.87M) USD
- Year-over-year change
- —
| Period | Period end | Income Before Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (39.87M) | — |
Income Before Tax vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $781.34M USD | -37.2% | +35.8% | 7.1% | |
| LTM Apr 2026 | -$19.56M USD | +68.1% | — | 6.7% | |
| LTM Mar 2026 | -$37.27M USD | +24.1% | — | 46.9% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | -$39.87M USD | — | — | — |
| LTM Mar 2026 | -$46.58M USD | -75.9% | — | 36.5% | |
| LTM Jun 2026 | -$65M USD | +83.5% | — | 1.2% | |
| LTM Mar 2026 | -CHF 95.35M CHF | +7.5% | — | 18919.2% | |
| LTM Jun 2026 | -$192.83M USD | -109.2% | — | 31.5% | |
| LTM Mar 2026 | -$271.37M USD | -85.0% | — | 3563.6% | |
| LTM Mar 2026 | -$290.5M USD | -50.7% | — | 558.2% | |
| Peer median (excluding SGP) | — | -37.2% | +35.8% | 36.5% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 612K |
| Gross Profit | (612K) |
| Gross Margin | — |
| Research & Development | 28.64M |
| Selling, General & Admin | 12.2M |
| Operating Expenses | 40.84M |
| Depreciation & Amortization | 612K |
| EBITDA | (39.26M) |
| EBITDA Margin | — |
| Operating Income | (41.45M) |
| Operating Margin | — |
| Interest Income | 3.11M |
| Interest Expense | 0 |
| Other Income / Expenses | 1.58M |
| Income Before Tax | (39.87M) |
| Pre-Tax Margin | — |
| Income Tax Expense | 0 |
| Net Income | (39.87M) |
| Net Margin | — |
| EPS (Basic) | (1.19) |
| EPS (Diluted) | (1.19) |
| Weighted Avg Shares | 33.43M |
| Weighted Avg Shares (Diluted) | 33.43M |
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.